There is an urgent need for the healthcare industry to reposition safety: that is to change how the ability to discover, possess information about and act on predicted Adverse Drug Reactions (ADR) is perceived and treated by pharma companies, the regulator and other stakeholders. To date drug testing has been biased toward minimizing “Type I” … Read More
The increasing importance of predicting AEs & the role of Augmented Intelligence
By Andreas Persidis, CEO Biovista Inc. The increasing importance of predicting AEs & the role of Augmented Intelligence Case in point: precision medicine and drug repurposing. The approval of a drug has to date been the result of the careful assessment of its benefit-to-risk ratio. In this analysis, the benefit (efficacy) side of the equation … Read More
Extreme user profiling: good or bad for search and scientific discovery?
By Andreas Persidis, CEO Biovista Inc. Are you by any chance, like me, beginning to get the feeling that when you are searching online, your digital profile may be getting in the way? That too much of this “personalized” cerebral pampering, too much of this “right information, to the right person at the right time” … Read More
Why Systematic Drug Repurposing is here to stay
Why Systematic Drug Repurposing (SDR) is here to stay. The article gives 5 reasons why SDR will continue to be used as a tool for developing new therapies that are more affordable and make better use of our existing knowledge of disease pathology, drug performance and other date from the real world evidence surrounding treatments.
How to develop differentiated therapies cost effectively: NCEs, repositioned drugs or both?
Andreas Persidis, CEO Everybody agrees that the success of a drug increasingly depends on the total value it delivers. The commercial performance to date of Lundbeck’s antidepressant Brintellix is a case in point. Having demonstrated statistically significant efficacy over placebo in study results reported in 2012, Brintellix was approved by the FDA in 2013. Brintellix’s … Read More